Rydar Equities’s GSK GSK Stock Holding History

Rydar Equities’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.46K	Buy	+137	New	+$7K	﹤0.01%	336

Other funds holding GSK

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

Sound Income Strategies Ft Lauderdale, Florida $2.24B AUM 8.38% 1-Year Est. Return

Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return

KFP

Keystone Financial Planning Cleveland, Ohio $404M AUM 16.77% 1-Year Est. Return

KIC

Keating Investment Counselors Delray Beach, Florida $382M AUM 16.71% 1-Year Est. Return

Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return

Gilman Hill Asset Management New Canaan, Connecticut $718M AUM 15.3% 1-Year Est. Return

ARS Wealth Advisors Group St. Petersburg, Florida $1.37B AUM 18.29% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

RWA

Roberts Wealth Advisors Palo Alto, California $445M AUM 20.18% 1-Year Est. Return

Rydar Equities's GSK Position: Q3 2026 in Review

Rydar Equities opened a new position in GSK (GSK) in Q3 2026: 137 shares worth $6.46K. The stake represents ﹤0.01% of the portfolio and ranks #336 among its holdings.

155 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

Rydar Equities held 137 shares of GSK worth $6.46K as of Q3 2026.
GSK was a new Rydar Equities position in Q3 2026.
GSK made up ﹤0.01% of Rydar Equities's portfolio in Q3 2026, its #336 holding.
155 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Rydar Equities's 13F filing for Q3 2026, filed 13 Oct 2026.